The short version
- Semaglutide works mainly by reducing hunger and how much you eat, not by burning extra calories.
- In studies, most of the weight lost was fat, but a meaningful share was lean mass, which includes muscle.
- Resistance training at least two days a week and enough protein help protect muscle during weight loss.
- Weight usually returns after stopping, so habits built during treatment matter.
- Semaglutide is a prescription medicine that needs a medical evaluation; compounded versions are not FDA-approved.
Does semaglutide actually burn fat?
No, not in the way the phrase suggests. Semaglutide does not make your body burn more calories or dissolve fat cells. It mainly reduces your appetite, so you eat less. When you take in fewer calories than you use, your body pulls energy from storage, and much of that comes from fat.
So the honest answer is that semaglutide leads to fat loss indirectly. The fat is still burned by your own metabolism, the same way it is with any calorie deficit. The medicine makes that deficit easier to reach and keep.
What is semaglutide?
Semaglutide is a prescription medicine in a class called GLP-1 receptor agonists. It is sold as Wegovy, which is FDA-approved for chronic weight management, and as Ozempic, which is approved for type 2 diabetes. At our Dallas clinic, it is prescribed only after a medical evaluation by our physician as part of medical weight loss.
How does semaglutide cause weight loss?
Semaglutide copies a natural gut hormone called GLP-1, which your body releases after meals. It acts on appetite centers in the brain and slows how quickly your stomach empties. Together, these make you feel full sooner and stay full longer.
A 12-week study measured what people ate at buffet-style meals. Compared with placebo, people taking semaglutide ate about 24 percent fewer calories across the day. They also reported less hunger, fewer food cravings and better control over eating. Their resting metabolic rate, adjusted for body composition, did not change.
| Common belief | What the research shows |
|---|---|
| It speeds up metabolism | Resting metabolic rate did not change beyond what body size predicts |
| It melts fat directly | It lowers calorie intake, and the body uses stored fat |
| All weight lost is fat | Most is fat, but some is lean mass |
| Results last after stopping | Most people regain much of the weight |
How much of the weight lost is fat?
Most of it, but not all. In the main trial of semaglutide for weight management, adults lost about 15 percent of their body weight on average over 68 weeks. A smaller group had body scans. They lost more fat than lean mass, and the share of their body made up of lean mass went up, even though the total amount of lean mass went down.
Why does lean mass matter?
Lean mass is everything that is not fat: muscle, organs, bone and water. Researchers who reviewed GLP-1 studies found the share of weight lost as lean mass varied widely, from about 15 percent in some studies to 40 percent or more in others. Part of that spread comes from how lean mass is measured, since it is not the same as muscle.
Muscle still matters. It supports your joints and spine, helps you balance, and keeps you strong for daily tasks. Losing too much is a bigger concern for older adults and people who are already frail. Some newer imaging studies suggest muscle quality may improve as fat inside the muscle drops, but this is still being studied.
How can you protect muscle while taking semaglutide?
The two most practical steps are resistance training and enough protein. An advisory from four obesity and nutrition medical groups lists preserving muscle and bone through resistance training and an appropriate diet as a priority during GLP-1 treatment.
- Strength train at least two days a week. Federal guidelines recommend muscle-strengthening activity for all major muscle groups at least two days a week. Bodyweight moves, bands, machines or free weights can all work.
- Prioritize protein at each meal. With a smaller appetite, eat the protein portion of your meal first. Spread it across the day instead of saving it for dinner.
- Keep moving. Aim for about 150 minutes of moderate activity a week, such as brisk walking, as you are able.
- Get a personal target. Protein needs depend on your size, age, kidney health and activity, so ask your physician or a dietitian.
- Track strength, not just weight. Notice whether daily tasks and lifts feel easier or harder over time.
If back, hip or knee pain makes exercise hard, a guided program through physical rehab can help you start safely. Losing weight can also reduce load on painful joints, which is part of why it may help with knee pain and low back pain.
What happens when you stop semaglutide?
Most people regain a large share of the weight. In a follow-up of the main trial, people who stopped semaglutide regained about two thirds of the weight they had lost within a year. Improvements in blood pressure and blood sugar also faded.
This does not mean the medicine failed. It means obesity is a long-term condition. Habits built while on the medicine, especially strength training and eating patterns, are what you keep if you stop.
What else should you know before starting?
Semaglutide is not a supplement or a quick fix. It is a prescription medicine with real side effects. The most common are nausea, diarrhea, vomiting and constipation. It carries a boxed warning about thyroid C-cell tumors seen in rodents and is not used in people with a personal or family history of medullary thyroid cancer or MEN 2.
Is compounded semaglutide the same thing?
No. Compounded versions are not FDA-approved, and the FDA does not review them for safety, effectiveness or quality. The agency has reported hospitalizations linked to dosing errors with these products. Only FDA-approved products, such as Wegovy and Ozempic, have been tested and approved for their labeled uses.
A medical evaluation helps decide whether semaglutide fits you, which dose to use, and how to watch for side effects. You can read about how our physician handles that process on our medical weight loss page.
Frequently asked questions
It does not target one area. Like other ways of losing weight, it reduces fat throughout the body. Studies using body scans have found that fat stored deep in the abdomen around the organs also decreases, which matters because that type of fat is linked to heart and metabolic disease. Where you lose fat first depends partly on your genes.
Some lean mass loss is expected with any significant weight loss, and studies of semaglutide show it too. The amount varies a lot between people and studies. Lean mass also includes water, organs and bone, so it is not all muscle. Resistance training and enough protein are the most practical ways to protect the muscle you have.
Needs depend on your size, age, kidney health and activity level, so there is no single number that fits everyone. Expert groups recommend paying close attention to protein during GLP-1 treatment because appetite drops and meals get smaller. Spreading protein across meals helps. Ask your physician or a registered dietitian for a target that fits you.
In a study measuring resting metabolic rate, semaglutide did not change it beyond what was expected from body size. Any weight loss tends to lower the number of calories your body burns, because a smaller body needs less energy. Keeping muscle through strength training can help limit that drop.
Wegovy is approved for use together with a reduced-calorie diet and more physical activity, and the trials included lifestyle counseling. Eating well matters even more when appetite is low, to get enough protein, vitamins and minerals. Exercise, especially strength training, helps you keep muscle and supports long-term results.
Sources
- Blundell et al. 2017: Effects of semaglutide on appetite, energy intake and body composition (PubMed) (opens in a new tab)
- Wilding et al. 2021: Once-weekly semaglutide in adults with overweight or obesity, STEP 1 (PubMed) (opens in a new tab)
- Neeland et al. 2024: Changes in lean body mass with GLP-1-based therapies (PubMed) (opens in a new tab)
- Mozaffarian et al. 2025: Nutritional priorities to support GLP-1 therapy for obesity, joint advisory (PubMed) (opens in a new tab)
- Wilding et al. 2022: Weight regain after withdrawal of semaglutide (PubMed) (opens in a new tab)
- CDC: Physical activity guidelines for adults (opens in a new tab)
- MedlinePlus: Semaglutide injection (opens in a new tab)
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (opens in a new tab)
This page is general education, not medical advice. It cannot replace an exam. Results from any treatment vary from person to person.




